Pierre Fabre and Iktos: AI Accelerates Cancer Drug Discovery

Pharmaceutical group Pierre Fabre Laboratories and Iktos, a leader in generative chemistry, announced the start of a joint project on January 9, 2026. The collaboration aims to use the Iktos AI platform to design new small molecules for oncology treatment.

Iktos technology combines generative deep learning models with automated synthesis, radically reducing the "Design-Make-Test-Analyze" (DMTA) cycle time. Pierre Fabre provides its data and biological targets, while the AI generates candidate structures with optimal properties. This partnership highlights the trend toward the industrialization of AI Drug Discovery, where algorithms become the primary tool for early drug development.

Source: Pierre Fabre